| 5.27 -0.12 (-2.23%) | 09-18 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 6.93 | 1-year : | 7.74 |
| Resists | First : | 5.94 | Second : | 6.62 |
| Pivot price | 5.58 |
|||
| Supports | First : | 4.82 | Second : | 4.01 |
| MAs | MA(5) : | 5.52 |
MA(20) : | 5.53  |
| MA(100) : | 6.1 |
MA(250) : | 6.31 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 26.7 |
D(3) : | 34.1 |
| RSI | RSI(14): 44.8 |
|||
| 52-week | High : | 16.23 | Low : | 1.27 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ NKTX ] has closed above bottom band by 30.0%. Bollinger Bands are 7.2% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 5.64 - 5.69 | 5.69 - 5.72 |
| Low: | 5.13 - 5.18 | 5.18 - 5.21 |
| Close: | 5.21 - 5.28 | 5.28 - 5.33 |
Nkarta, Inc., a a clinical-stage biopharmaceutical company, develops and commercializes cell therapies for cancer treatment. The company's approach for cellular immunotherapy involves chimeric antigen receptors on the surface of a natural killer (NK) cell that enable the cell to recognize specific proteins or antigens that are present on the surface of tumor cells. Its two co-lead product candidates are NKX101, which is in Phase I clinical trials for the treatment of relapsed/refractory acute myeloid leukemia or higher risk myelodysplastic syndromes; and NKX019, a pre-clinical product, which is based on the ability to treat various B cell malignancies by targeting the CD19 antigen found on these types of cancerous cells. The company has a research collaboration agreement with CRISPR Therapeutics AG. Nkarta, Inc. was incorporated in 2015 and is based in South San Francisco, California.
Sun, 15 Sep 2024
Nkarta, Inc. (NASDAQ:NKTX) Stock Holdings Lifted by Acadian Asset Management LLC - MarketBeat
Tue, 03 Sep 2024
Nkarta to Participate in Upcoming Investor Conference - GlobeNewswire
Wed, 14 Aug 2024
Nkarta stock upgraded at Raymond James (NASDAQ:NKTX) - Seeking Alpha
Tue, 13 Aug 2024
Nkarta Reports Second Quarter 2024 Financial Results and Corporate Highlights - GlobeNewswire
Sat, 25 May 2024
Nkarta Stock: Finally An Attractive Valuation (NASDAQ:NKTX) - Seeking Alpha
Thu, 23 May 2024
Nkarta: A Look Into Q1 Results And Upcoming Catalysts (NASDAQ:NKTX) - Seeking Alpha
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 71 (M) |
| Shares Float | 35 (M) |
| Held by Insiders | 4.8 (%) |
| Held by Institutions | 98.7 (%) |
| Shares Short | 8,350 (K) |
| Shares Short P.Month | 7,130 (K) |
| EPS | -1.98 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 6.42 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -15.7 % |
| Return on Equity (ttm) | -28 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -1.62 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -94 (M) |
| Levered Free Cash Flow | -73 (M) |
| PE Ratio | -2.68 |
| PEG Ratio | 0 |
| Price to Book value | 0.82 |
| Price to Sales | 0 |
| Price to Cash Flow | -3.96 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|